Comparison of methods of analysis of body composition in hypophysectomized rats treated with rat growth hormone.
The present study compared estimates of body composition derived from dual-emission X-ray absorptiometry (DEXA) and from chemical analyses. The primary aim was to compare the two methods because growth hormone (GH) may cause fluid retention, and DEXA does not distinguish water from lean mass. Hypophysectomized rats were fed ad libitum and were treated with continuous infusions of rat GH in doses of 0, 10, 30, and 100 microg/day for 14 days. By chemical analysis, a decrease in percentage fat from 12.9% in the control group to 11.3%, 11.0%, and 10.2% in the low, medium, and high dose groups was observed (P < 0.0001). The fat percentages were about 3-4% higher by DEXA, but showed the same decline (P < 0.03). Lean mass increased from 74.4% in the control group to 75.8%, 78.0%, and 78.6% in the treatment groups (P < 0.001). A significant increase in the wet weight of the quadriceps muscle, but no difference in dry weight was observed in all four treatment groups, indicating that the increase in muscle weight was exclusively caused by water. This accumulation of water was reflected in the total water content of the carcasses, which increased from 62.0% in the control group to 64.9%, 66.1%, and 66.8% in the GH groups (P < 0.0001). The protein content decreased from 19.8% in the control group to 19.4%, 19.1%, and 18.9% in the GH groups (P < 0.001). Regardless of the decrease in protein, the GH treated groups contained more water in relation to protein as the g water/g protein ratio was increased by 13% from 3.14 in the control group to 3.55 in the group treated with the highest GH dose (P < 0.0001). Also, a close relationship between feed intake and body weight were found, together with increases in epiphyseal growth plate width, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding protein 3 (IGFBP-3). In conclusion, the study shows that estimation of lean mass by DEXA should be carefully evaluated when used in connection with treatment of drugs that cause water retention.
Johansen
P B
PB
Department of Pharmacological Research 3, Health Care Discovery, Novo Nordisk A/S, Bagsvaerd, DK-2880, Denmark. pjoh@novonordisk.com
Flyvbjerg
A
A
Wilken
M
M
Malmlöf
K
K
D015502:Absorptiometry, Photon / Q000379:methods*; D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D015992:Body Mass Index; D004305:Dose-Response Relationship, Drug; D013006:Growth Hormone / Q000627:therapeutic use*; D007016:Hypophysectomy; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014867:Water / Q000378:metabolism
D018972:Insulin-Like Growth Factor Binding Protein 3; D014867:Water; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone